References
1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Reports . 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1
2. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med . 2015;162(4):276-286. doi:10.7326/M14-2559
3. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ . 2017;189(18):E659-E666. doi:10.1503/cmaj.170363
4. Inturrisi CE. Clinical Pharmacology of Opioids for Pain .; 2002.
5. WHO | Information sheet on opioid overdose. WHO . 2018.
6. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. Adults: 2015 national survey on drug use and health. Ann Intern Med . 2017;167(5):293-301. doi:10.7326/M17-0865
7. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research : Health and Medicine Division. http://www.nationalacademies.org/hmd/Reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx. Accessed December 1, 2019.
8. (No Title). https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf. Accessed December 1, 2019.
9. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys.Toxicol Appl Pharmacol . 1973;25(3):363-372. doi:10.1016/0041-008X(73)90310-4
10. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction . 2010;105(3):494-503. doi:10.1111/j.1360-0443.2009.02776.x
11. Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: Involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol . 2013;18(2):286-296. doi:10.1111/j.1369-1600.2012.00483.x
12. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology . 2018. doi:10.1038/s41386-018-0011-2
13. Nielsen S, Sabioni P, Trigo JM, et al. Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis.Neuropsychopharmacology . 2017. doi:10.1038/npp.2017.51
14. Lake S, Walsh Z, Kerr T, et al. Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. Alegria M, ed. PLOS Med . 2019;16(11):e1002967. doi:10.1371/journal.pmed.1002967
15. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther . 2011;90(6):844-851. doi:10.1038/clpt.2011.188
16. Ware MA, Wang T, Shapiro S, Collet JP. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain . 2015;16(12):1233-1242. doi:10.1016/j.jpain.2015.07.014
17. Haroutounian S, Ratz Y, Ginosar Y, et al. The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain . 2016;32(12):1036-1043. doi:10.1097/AJP.0000000000000364
18. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and Efficacy of Medical Cannabis in Fibromyalgia. J Clin Med . 2019;8(6):807. doi:10.3390/jcm8060807
19. Rod K. A Pilot Study of a Medical Cannabis - Opioid Reduction Program. Am J Psychiatry Neurosci . 2019;7(3):74. doi:10.11648/j.ajpn.20190703.14
20. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.Eur J Intern Med . 2018;49:44-50. doi:10.1016/j.ejim.2018.01.019
21. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy . 2017;42:30-35. doi:10.1016/j.drugpo.2017.01.011
22. Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J . 2019;16(1):9. doi:10.1186/s12954-019-0278-6
23. Lucas P, Walsh Z, Crosby K, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug Alcohol Rev . 2016;35(3):326-333. doi:10.1111/dar.12323
24. Wildes M, Bigand TL, Layton ME, Wilson M. Cannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain. Pain Manag Nurs . 2019. doi:10.1016/j.pmn.2019.06.014
25. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Heal . 2018;3(7):e341-e350. doi:10.1016/S2468-2667(18)30110-5
26. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. doi:10.1089/can.2017.0012
27. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain. J Pain . 2016;17(6):739-744. doi:10.1016/j.jpain.2016.03.002
28. Hamilton I, Monaghan M. Cannabis and Psychosis: Are We any Closer to Understanding the Relationship? Curr Psychiatry Rep . 2019;21(7). doi:10.1007/s11920-019-1044-x
29. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol Med . 2014;44(4):797-810. doi:10.1017/S0033291713001438
30. Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.Am J Public Health . 2017;107(8):e1-e12. doi:10.2105/AJPH.2017.303818
31. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med . 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309
32. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Cannabis Cannabinoid Res . 2017;2(1):139-154. doi:10.1089/can.2016.0034
33. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA - J Am Med Assoc . 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
34. Russo EB. Cannabis and Pain. Pain Med . September 2019. doi:10.1093/pm/pnz227
35. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs . 2000;32(4):1008-1015. doi:10.1046/j.1365-2648.2000.t01-1-01567.x
36. Starrels JL, Young SR, Azari SS, et al. Disagreement and Uncertainty Among Experts About how to Respond to Marijuana Use in Patients on Long-term Opioids for Chronic Pain: Results of a Delphi Study.Pain Med . August 2019. doi:10.1093/pm/pnz153
37. Dalkey N. An experimental study of group opinion: The Delphi method.Futures . 1969. doi:10.1016/S0016-3287(69)80025-X
38. Dalkey N, Helmer O. An Experimental Application of the DELPHI Method to the Use of Experts. Manage Sci . 1963. doi:10.1287/mnsc.9.3.458
39. Saad F, Canil C, Finelli A, et al. A Canadian consensus forum on the management of patients with advanced prostate cancer. Can Urol Assoc J . 2019;14(4). doi:10.5489/cuaj.6082
40. PAINWeek 2019 Accepted Abstracts by PAINWeek - issuu. https://issuu.com/painweek/docs/accepted_full_abstracts_by_poster_number_8.26.19. Accessed December 16, 2019.
41. Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]. In:European Urology . ; 2018. doi:10.1016/j.eururo.2017.06.002
42. Eubank BH, Mohtadi NG, Lafave MR, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol . 2016;16(1). doi:10.1186/s12874-016-0165-8
43. Stewart D, Gibson-Smith K, MacLure K, et al. A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people. Leong C, ed. PLoS One . 2017;12(11):e0188348. doi:10.1371/journal.pone.0188348
44. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol . 2014;67(4):401-409. doi:10.1016/j.jclinepi.2013.12.002
45. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry . 2018;175(3):225-231. doi:10.1176/appi.ajp.2017.17030325
46. Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl) . 2018;235(7):1923-1932. doi:10.1007/s00213-018-4885-9
47. Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med . 2019;380(24):2285-2287. doi:10.1056/NEJMp1904190
48. Tick H, Nielsen A, Pelletier KR, et al. Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium Pain Task Force White Paper. Explore . 2018;14(3):177-211. doi:10.1016/j.explore.2018.02.001
49. PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE REPORT .; 2019.
50. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med . 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
51. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N Engl J Med . 2018;378(20):1888-1897. doi:10.1056/NEJMoa1714631
52. Arain M, Haque M, Johal L, et al. Maturation of the adolescent brain. Neuropsychiatr Dis Treat . 2013;9:449-461. doi:10.2147/NDT.S39776
53. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther . 1976;19(3):300-309. doi:10.1002/cpt1976193300
54. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med . November 2019:1-6. doi:10.1080/00325481.2019.1685298
55. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry . 2019;176(11):911-922. doi:10.1176/appi.ajp.2019.18101191
56. Li X, Vigil JM, Stith SS, Brockelman F, Keeling K, Hall B. The effectiveness of self-directed medical cannabis treatment for pain.Complement Ther Med . 2019;46:123-130. doi:10.1016/j.ctim.2019.07.022
57. Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. The Association between Cannabis Product Characteristics and Symptom Relief. Sci Rep . 2019;9(1). doi:10.1038/s41598-019-39462-1
58. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler . 2004;10(4):434-441. doi:10.1191/1352458504ms1082oa
59. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil . 2003;17(1):21-29. doi:10.1191/0269215503cr581oa
60. Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. Osteoarthr Cartil . 2018;26:S26. doi:10.1016/j.joca.2018.02.067
61. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol . 2019;20. doi:10.2174/1389201020666191202111534
62. Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.J Pain . 2015;16(12):1221-1232. doi:10.1016/j.jpain.2015.07.009
63. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage . 1995;10(2):89-97. doi:10.1016/0885-3924(94)00117-4
64. Matheson J, Sproule B, Di Ciano P, et al. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacology (Berl) . 2019. doi:10.1007/s00213-019-05369-y
65. Boehnke KF, Clauw DJ. Brief commentary: Cannabinoid dosing for chronic pain management. Ann Intern Med . 2019;170(2):118. doi:10.7326/M18-2972
66. Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: A critical review on clinical trials. Exp Clin Psychopharmacol . 2019;27(4):383-401. doi:10.1037/pha0000285
67. Manwell LA, Charchoglyan A, Brewer D, Matthews BA, Heipel H, Mallet PE. A vapourized δ9-tetrahydrocannabinol (δ9-THC) delivery system part I: Development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. J Pharmacol Toxicol Methods . 2014;70(1):120-127. doi:10.1016/j.vascn.2014.06.006
68. Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin — Preliminary Report.N Engl J Med . September 2019. doi:10.1056/nejmoa1911614
69. Kalininskiy A, Bach CT, Nacca NE, et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med . 2019;7(12):1017-1026. doi:10.1016/S2213-2600(19)30415-1
70. Rubin R. HHS Guide for Tapering or Stopping Long-term Opioid Use.JAMA . 2019;322(20):1947. doi:10.1001/jama.2019.18979
71. CDC. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics .
72. Morris NP. Educating Physicians about Marijuana. JAMA Intern Med . 2019;179(8):1017-1018. doi:10.1001/jamainternmed.2019.1529
73. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana.Drug Alcohol Depend . 2017;180:151-155. doi:10.1016/j.drugalcdep.2017.08.010